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Take home message: Largest prospective study investigating unilateral pleural effusions; the value 
of cytology depends on the primary.   
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Abstract 
 
The vast majority of undiagnosed unilateral pleural effusions have fluid sent for cytological analysis. 
Despite widespread use, there is uncertainty about its sensitivity to diagnose malignant pleural 
effusions (MPEs). Our aim was to ascertain the utility of cytology using a large prospective cohort.  
Consecutive patients presenting with an undiagnosed unilateral pleural effusion were recruited to 
this UK-based study. All had pleural fluid sent for cytological analysis. Cytological sensitivity was 
based on the final diagnosis at 12 months, confirmed by two consultants.  
Over 8-years, 921 patients were recruited, of which 515 had a MPE. Overall sensitivity of fluid 
cytology to diagnose malignancy was 46% (95%CI 42-58). There was variation in sensitivity 
depending on cancer primary, with mesothelioma (6%) and haematological malignancies (40%), 
being significantly lower than adenocarcinomas (79%). MPEs secondary to ovarian cancer had high 
pick-up rates (95%). In asbestos-exposed males with exudative effusions, the risk of MPE was 60%, 
but cytological sensitivity was 11%.  
This is the largest prospective study of pleural fluid cytology and informs discussions with patients 
about the likely requirement for investigations following thoracentesis. In patients presenting with a 
clinical suspicion of mesothelioma, cytological sensitivity is low, so more definitive investigations 
could be performed sooner.  
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Introduction  
Pleural fluid analysis with cytological assessment is a fundamental part of the investigation of 
unilateral pleural effusions. In Europe and North America, one of the commonest causes is primary 
or secondary pleural malignancy[1]. Identifying malignancy from pleural fluid cytology alone can 
spare patients from more invasive investigations, reduces healthcare costs, is important for staging, 
and allows earlier progression to treatment. However, it has several drawbacks including an 
uncertain sensitivity, and extending the time (routinely between 5 to 7 days) before further 
investigations are organised [2].  
The estimates of sensitivity for detecting malignancy from pleural fluid cytology vary greatly within 
guidelines, ranging from 40-87%[1, 3]. The reason for this variation is due to retrospective study 
designs[4-7], selective study inclusion criteria[8, 9] and a variation in cytopathological methods. 
Additionally, most studies of cytological yield cited in guidelines are over 20 years old. There has 
been a significant advance in immunohistochemical methods since then.  
Better knowledge of the discriminative ability of pleural fluid cytology would allow, not only more 
informed consultations with patients, but better planning of further investigations. This study uses a 
large prospective cohort of patients with undiagnosed unilateral pleural effusions to assess 
cytological sensitivity depending on cancer type and patient factors. It aims to inform practice for 
respiratory physicians when diagnosing malignant pleural effusions.  
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Methods 
Patients 
Consecutive patients referred to a single centre pleural service with an undiagnosed unilateral 
pleural effusion were recruited to this prospective observational study. All patients had a diagnostic 
thoracentesis as part of normal clinical care and consented to having their demographic data, blood 
and pleural fluid results stored. The study received ethical approval from the South West regional 
ethics committee (REC number 08/H0102/11). All patients were followed up to 12 months or death 
(whichever occurred first) and were assigned a final diagnosis as to the pathology or pathologies 
most likely to be the cause of their effusion. The final diagnosis was agreed by two independent 
consultant respiratory physicians based on all the available clinical, histological and radiological 
information. Any areas of contention were re-examined till consensus was reached.  
 
Serum and pleural fluid analysis 
All patients had routine pleural fluid analysis at baseline, including protein, glucose, LDH, pH, 
microbiology culture, and cytology. Light’s criteria were used to distinguish exudative from 
transudative effusions[10].  Predominant pleural fluid cell types were defined based on British 
Thoracic Society guidelines[1]. A lymphocyte or neutrophil predominant effusion was defined as the 
presence of over 50% of that cell type in the absence of ≥10% eosinophils, in which case the effusion 
was deemed eosinophilic. Any effusion not meeting any of the above criteria was classed ‘non-
specific’, i.e. both lymphocytes and neutrophils<50%, eosinophils <10%, with another cell type 
predominating (e.g. mesothelial, blood or atypical cells). Routine baseline blood tests were also 
performed. The serum neutrophil/lymphocyte ratio (a widely used indicator of poor prognosis for 
malignancy[11]) was calculated by dividing the serum neutrophils (109/L) by serum lymphocytes.  
 
Pleural fluid cytology and immunohistochemistry 
As per guidelines, 40ml of pleural fluid was sent for cytological analysis where possible[1]. It is 
standard practice in our centre that after preparing slides from the centrifuged deposit, all pleural 
fluid cytology samples have a formalin fixed paraffin embedded cell block produced. All samples 
were reviewed by a consultant cytopathologist. Depending on the degree of clinical suspicion of 
malignancy and/or initial cytological assessment, immunostaining was requested. The panel of 
immunohistochemical stains often included EMA to distinguish between malignant cells and reactive 
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mesothelial cells. Markers to distinguish between adenocarcinoma cells (AUA1 or, in later years, 
BerEP4) and mesothelial cells (CK5/6 and Calretinin) were frequently used. In cases of 
adenocarcinoma, further immunostaining was undertaken to assess the most likely primary site. 
These markers included CK7, CK20, TTF1, ER (oestrogen receptor), PR (progesterone receptor) and 
Ca125. Overlap of staining patterns sometimes occurred, with variation in the exact panels used 
between patients, but generally this panel of immunohistochemical stains provided useful 
information for diagnosis. Flow cytometry for lymphoma was sent based on a previously published 
algorithm[12]. A full breakdown of positive immunohistochemical markers in malignant effusions is 
shown in Appendix 1. Samples that were ‘non-diagnostic’ for malignancy were those where a 
diagnosis of malignancy was not made based on the cytological specimen, with the patient requiring 
further investigations or interval radiological follow up. In this instance, and when malignancy was 
the most likely diagnosis, it was usual practice to proceed to definitive biopsy (e.g. thoracoscopy or 
CT guided biopsy), instead of repeating thoracentesis.  
 
Diagnostic criteria 
Predefined criteria were used to reach a 12-month diagnosis. Malignant effusions were diagnosed in 
the presence of any of the following criteria: (1) Malignant pleural fluid cytology or biopsy, (2) 
histologically confirmed pulmonary/extra-thoracic malignancy with radiographic evidence of 
metastasis to ipsilateral pleura on CT, (3) radiological changes meeting Leung’s criteria which have 
progressed in keeping with malignancy on interval CT scan in the correct clinical context, or (4) 
autopsy confirming pleural malignancy. See Appendix 2 for full details of diagnostic criteria for non-
malignant pathologies.  
 
Statistical analysis 
Descriptive statistics were used to summarise patient characteristics and clinical data. Sensitivity 
estimates with 95% C.Is were used to investigate the ability of pleural fluid cytology to detect 
malignancy. When comparing cytological sensitivity between two groups the classic Z-test was used 
with p <0.05 used to define significance. Pleural fluid characteristics amongst the cohort were 
reported using descriptive statistics, with differences between cytology diagnostic and non-
diagnostic effusions assessed using the independent samples T-test. Survival (from study entry) was 
censored at 20.12.17.  
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Results 
 
Patient demographics 
Between December 2008 and December 2016, 921 consecutive patients presenting with an 
undiagnosed unilateral pleural effusion were recruited.  All had a diagnostic thoracentesis for 
standard pleural fluid investigations, with 40ml of fluid sent for cytological analysis in the majority 
(median 40ml, IQR 35-40ml). The cohort had a mean age of 70.2 (SD 13.8) and had a male 
predominance. The baseline characteristics of the cohort are shown in Table 1.  
 
Table 1- Demographics 
 All Malignant Non-malignant 
Total 921 515 406 
Mean Age 70 72 68 
Sex (M:F) 601:320 317:198 284:122 
Laterality (L:R) 385:536 222:293 163:243 
Previous malignancy 212 176 36 
Median Survival days 
(IQR) 
474 (127-1632) 199 (74-465) 1700 (831-2522) 
Asbestos exposure 274 166 108 
    
PF analysis    
Transudate (%) 118 (13) 21 (4) 97 (24) 
    
Predominant PF cell type    
Lymphocytic (%) 315 (34) 183 (35) 132 (33) 
Neutrophilic (%) 87 (9) 13 (3) 74 (18) 
Eosinophilic (%) 71 (8) 30 (6) 41 (10) 
Non specific (%) 448 (49) 289 (56) 159 (39) 
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Effusion diagnoses 
The majority of effusions had a malignant aetiology at 12-month consultant diagnosis (56%), see 
Table 1. There were 6 patients where the exact cause of the effusion could not be ascertained. In all 
6, malignancy was excluded given resolution of effusion on follow-up imaging, so these cases have 
been placed in the non-malignant group for further analysis. Table 2 shows the breakdown of the 
malignant effusions by primary site. Lung was the most numerous cancer primary causing effusions 
within this cohort (32%, 166/515), with effusions secondary to mesothelioma accounting for 29% 
(148/515) of the malignant diagnoses.  
 
Table 2- Cytological sensitivity by cancer type  
 No. in cohort PF cytology 
diagnostic 
Sensitivity (95% C.I.) 
All 515 239 46.4% (42.0-58.2) 
Breast 58 41 70.7% (57.3-81.9) 
ENT 7 1 14.3% (0.4-57.9) 
Gastrointestinal 22 15 68.2% (45.1-86.1) 
Haematological 30 12 40.0% (22.6-59.4) 
Lung (all) 
- Adenocarcinoma 
- Squamous 
- Small cell 
- Other/unknown 
166 
100 
28 
16 
22 
93 
82 
4 
7 
0 
56.0% (48.1-63.7) 
82.0% (73.1-89.0) 
14.3% (4.0-32.7) 
43.8% (19.8-70.1) 
0% (0-15.4) 
Mesothelioma 148 9 6.1% (2.8-11.2) 
Sarcoma/Melanoma 8 0 0% (0-36.9) 
Ovarian 38 36 94.7% (82.2-99.4) 
Urological 17 2 11.8% (1.5-36.4) 
Unknown malignancy 21 7 33.3% (14.6-57.0) 
 
 
Cytological sensitivity by cancer primary 
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The sensitivity of pleural fluid cytology for detecting different cancer types is shown in Table 2 and 
Figure 1 with 95% confidence intervals. Cytology has a higher sensitivity for detecting 
adenocarcinomas compared to other cancer types, even once mesothelioma is excluded (p<0.01). 
Within adenocarcinomas, there is a significant difference depending on cancer primary with ovarian 
cancer having a significantly higher diagnostic rate than breast, lung or GI malignancies, which all 
have similar sensitivities (p-0.013). Mesothelioma had a low sensitivity for detection on pleural fluid 
cytology alone with 94% of patients requiring a definitive biopsy before a diagnosis could be made. 
Of the 30 patients with a malignant effusion secondary to haematological malignancy (23 patients 
with lymphoma and 7 with leukaemia), less than half had clear evidence of malignancy on pleural 
fluid cytology. Flow cytometry was performed in 21 of these patients and assisted in the diagnosis 
of16. Malignant effusions from rarer primary sites such as urogenital, ENT or musculoskeletal had 
low diagnostic rates, but numbers were small. Of the 276 non-diagnostic malignant pleural effusions, 
248 (90%) had a definitive histocytological diagnosis of malignancy (65% pleural biopsy, 24% biopsy 
from non-pleural tumour site with radiographic evidence of metastatic pleural disease, 1% post 
mortem). Pleural fluid cytology was repeated in 106 of these cases, often at the time of 
thoracoscopy or in patients unfit for more invasive investigations. Six of these samples were 
diagnostic for malignancy (5.6%). Thirty patients had a 3rd sample sent, all of which were non-
diagnostic. There was no difference in overall cytological sensitivity if more pleural fluid was sent for 
analysis. Overall sensitivity was 48% in samples of 40ml or less, compared to 40% in fluid samples 
over 40ml (p=0.65) 
 
Figure 1- Scatter plot of sensitivity of pleural fluid cytology by malignancy  
(Error bars represent 95% C.I.) 
 
Immunohistochemistry/Cytogenetic results 
The full results of positive immunohistochemistry and cytogenetic markers are shown in Appendix 1. 
It is of note that cytogenetic practice has advanced significantly during the course of the 8 years of 
recruitment. Therefore, certain tests e.g. epidermal growth factor receptor (EGFR), have only 
become available towards the end of the study period, and were only requested if clinically 
indicated. There were 41 instances where further genetic information was request on the pleural 
fluid cell block. Two of the cell blocks had insufficient material for further analysis (5%).  
 
 9 
 
Diagnostic flow chart; Risk of malignancy and sensitivity of pleural fluid cytology 
Figure 2 is a flowchart demonstrating the variation in the risk of malignancy and sensitivity of pleural 
fluid cytology depending on basic patient characteristics and pleural fluid analysis. These factors 
have been chosen as they are easily obtainable and have the greatest discriminative value in 
malignancy risk and/or cytological sensitivity. Whether an effusion is an exudate or transudate has a 
considerable bearing on the risk of malignancy. Within this cohort the risk of malignancy was 15% 
(21/118) in transudative effusions, compared to 62% (495/803) in exudative effusions. Of the 21 
patients with malignancy in the context of a transudative effusion, half (n=11) had a concurrent 
diagnosis of cardiac failure. The malignancies were 2 breast cancers, 5 lung cancers, 8 
mesotheliomas, 6 other types.  
The likelihood of malignancy in exudative effusions was over 60% and sensitivity of cytology 
remained over 40%. Amongst female patients with an exudative effusion, the likelihood of 
malignancy was high (67%), as was the sensitivity of cytology (66%). Male patients with a previous 
history of cancer (excluding prostate cancer) had a high risk of malignancy and cytological sensitivity 
remained over 40%.  
Within the subgroup of asbestos exposed male patients without a history of cancer, the sensitivity of 
pleural fluid cytology fell to 11% (C.I. 6-17) which is significantly lower than other groups (p<0.01), 
despite a risk of malignancy of over 60%. The patients with malignancy in this subgroup had a high 
likelihood of a ‘suspicion of malignancy’ on their initial CT scan (117/132).  
 
 
Figure 2- Diagnostic flow chart demonstrating risk of malignancy and sensitivity of pleural fluid 
cytology  
*excluding prostate cancer. PFsens- Pleural fluid cytology sensitivity (presented with 95% C.I.s), Hx- 
History. 
 
 
Survival: cytology diagnostic versus non-diagnostic malignant effusions 
The median survival of all malignant effusions was 199 days (IQR 74-465). There was considerable 
variation depending on cancer type but there was no impact on survival between those with 
cytology diagnostic versus non-diagnostic effusions for individual cancers. For example, within lung 
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adenocarcinoma, survival for cytology diagnostic effusions was 114 days (47-281) compared with 97 
days (IQR 32-201) (p= 0.13). 
 
Characteristics of cytology diagnostic versus non-diagnostic adenocarcinomas 
Cytology diagnostic malignant effusions secondary to adenocarcinoma were more likely to have 
serum or pleural markers of increased inflammation. This included a higher serum 
neutrophil/lymphocyte ratio, higher C reactive protein, and a higher pleural fluid LDH. There was no 
significant difference in survival between the two groups (p=0.57). See Table 3.  
 
Table 3. Characteristics of cytology diagnostic versus non-diagnostic adenocarcinomas  
 Diagnostic (n=173) Non-diagnostic (n=45) P value 
Serum (SD)    
N/L ratio 7.19 (6.15) 5.05 (2.41) 0.02 
C Reactive protein 48.8 (53.5) 30.4 (27.8) 0.03 
    
Pleural fluid (SD)    
Protein 44.9 (9.2) 42.1 (8.55) 0.08 
Glucose 6.15 (9.56) 5.86 (1.66) 0.85 
LDH 919.1 (833.8) 644.9 (706.9) 0.03 
pH 7.38 (0.17) 7.35 (0.49) 0.70 
    
Median survival (IQR) 148 (56-425) 98 (40-241) 0.574 
SD- Standard deviation, N/L ratio- Neutrophil/Lymphocyte ratio, LDH- Lactate dehydrogenase, 
IQR- Interquartile range. 
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Discussion 
This is the largest ever prospective study examining the role of pleural fluid cytology in undiagnosed 
unilateral pleural effusions. With over 900 patients, we can give an accurate assessment of the 
strengths and limitations of cytological assessment. The size of this cohort has also allowed for 
analysis by cancer subtype and the construction of a diagnostic flowchart to demonstrate the 
likelihood of malignancy with the corresponding cytological sensitivity.  
An unexplained pleural effusion is a common diagnostic challenge for the respiratory physician. In 
Europe and North America, a common cause is primary or secondary malignancy. Therefore, pleural 
fluid cytology is an essential aspect of pleural fluid analysis but one that is poorly understood. It is 
recognised that sensitivity is low, but estimates vary widely within international guidelines (40-
87%)[1, 3]. This variation arises because estimates are based on retrospective analyses of hospital or 
outpatient data[4-7]. Porcel and colleagues published a series of 3077 undiagnosed pleural 
effusions, of which 840 had a malignant aetiology[13]. Overall, preliminary pleural fluid cytology was 
positive in 51% of malignant effusions, but due to geographical variation the prevalence of 
mesothelioma within the cohort was less than 1%, compared to 16% in our cohort.  They also 
demonstrated that cytology was more accurate in adenocarcinoma of the lung (78%), breast (68%) 
and ovary (70%). The data was collected retrospectively from 1994 to 2013, which could explain why 
estimates for sensitivity were lower than in the current study, given the advancement in 
immunohistochemical analysis. Retrospective series of lab cytology samples have also been 
published, with very large numbers (>5000)[14-17]. These report the number of samples where 
malignant cells were seen, which, although epidemiologically useful, is not linked to clinical 
information or final diagnosis so does not reflect a measure of sensitivity. 
Two studies have prospectively recruited and followed up patients to assess the accuracy of pleural 
fluid cytology. In 1979, Hirsch and colleagues recruited 300 patients who required diagnostic 
thoracentesis[18]. All patients were routinely followed up, but given the lack of modern diagnostics 
(i.e. CT scans) the final diagnosis was not identified in 20% of cases (compared to 0.6% in the current 
study). Malignancy was identified as a cause of the pleural effusion in 117 patients (39%). The 
sensitivity of pleural fluid cytology alone to identify malignancy was 54% (95% C.I. 44.4-63.1). Given 
the small numbers there was no subgroup analysis by cancer type or patient characteristics. A more 
recent study, from Thailand, prospectively recruited 353 patients who underwent a diagnostic 
thoracentesis[19]. There was a high prevalence of malignancy within the cohort (78%) with 1 case of 
mesothelioma. Pleural fluid cytology was diagnostic in 61% (95% C.I.55.5-66.9) of cases with a higher 
sensitivity in lung cancer (73.7%) compared to non-lung solid cancers (53.5%) and haematological 
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malignancy (35.5%). There was no further break down by cancer type or patient/fluid characteristics. 
However, the diagnostic criteria for malignancy were not robust with only 6% of cytology-negative 
malignant effusions having a definitive biopsy (compared to 90% in our cohort), with the remaining 
94% being defined as cancerous following a ‘response to chemotherapy’. This may account for the 
high prevalence of malignant effusions within this cohort and will significantly affect the estimate of 
sensitivity. Additionally, only 15ml of pleural fluid was sent for cytological analysis which is 
considerably less than recommended by guidelines[1, 20]. In the current study, 40ml of fluid was 
sent when possible. There was no significant difference in cytological sensitivity if less fluid was 
received, although numbers were small (44 samples less than 40ml).  
We have demonstrated that the overall sensitivity of pleural fluid cytology is slightly lower than the 
above prospective studies at 45%. The most likely reason for this is the high proportion of 
mesothelioma diagnoses in our cohort (29%). This has a significant impact given the significant 
variability in sensitivity depending on cancer type. Mesothelioma was particularly low with only 6% 
of cases being diagnosed on cytology alone. If the prevalence of mesothelioma is artificially lowered 
to be more in keeping with a typical European centre (around 10% of all malignant effusions) the 
sensitivity of pleural fluid cytology rises to 55%.  
Some centres from areas with very high mesothelioma incidence report higher predictive values 
from pleural fluid cytology, but these are not commonplace[21, 22]. In most UK and European 
centres patients will require definitive biopsy unless there is clear evidence of malignant mesothelial 
cells with corroborative immunohistochemical markers, especially given the medico-legal 
implications of the diagnosis.   
Cytological sensitivity from other cancers varied considerably by primary site and cell type. 
Adenocarcinomas from the breast, lung, ovary or GI tract could be reliably detected on pleural fluid 
cytology alone (with a combined sensitivity of 80%). Sensitivity approached 95% in ovarian cancer, 
which was significantly higher than other adenocarcinomas (p=0.013). The pleura is the most 
common site for extra-abdominal spread in ovarian cancer[23].It is hypothesized that most 
malignant effusions from ovarian cancer result from direct pleural invasion of the diaphragm, or the 
migration of malignant ascitic fluid through diaphragmatic defects[24]. This mode of spread may 
result in more malignant cells being present in fluid, as opposed to the other malignancies which 
cause effusions due to disrupting normal pleural fluid recycling at the parietal membrane[25].  
We have investigated the variation in cytological sensitivity within adenocarcinomas alone and 
found that cytology diagnostic effusions correlate with biochemical markers indicative of more 
advanced/inflammatory malignancy (higher serum NLR and CRP, and pleural fluid LDH). Several 
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previous smaller studies have correlated an increased cytological yield for other proxies of advanced 
tumours including lower pleural pH and glucose, macroscopic spread and survival[26-29]. It follows 
that more advanced tumours are likely to be cytology positive due to increased exfoliation of 
tumour cells into the effusion. However, we did not find the same relationship between survival and 
cytology positivity when assessing individual tumour types. This finding from previous studies is 
likely to be because adenocarcinomas with higher cytological sensitivity have slightly better overall 
survival e.g. breast and ovarian[30].  
This variation in the utility of pleural fluid cytology has significant implications for planning further 
investigations. Guidelines recommend waiting for the pleural fluid cytology result before proceeding 
to other invasive and costly investigations (e.g. local anaesthetic thoracoscopy or CT guided 
biopsy)[1]. This can take between 5 to 7 days (or longer if additional immunohistochemistry is 
required), and the patient may still be symptomatic without definitive pleural drainage. This study 
has shown that in asbestos exposed male patients with no history of cancer, the likelihood of a 
diagnosing malignancy from an exudative effusion is just 6%, despite the risk of malignancy being 
over 60%. For this patient demographic we would support the approach of not waiting for the 
cytology result before performing a definitive biopsy. This is further supported by the finding that 
nearly 90% of the patients with a malignant effusion in this group had evidence of malignancy on 
their CT scan (117/132). In contrast, for patients not fulfilling these criteria, the higher sensitivity of 
pleural fluid cytology (>40%) justifies waiting for the result.  
This study has weaknesses that may limit the generalisability of its findings. This was a single centre 
study, however, the cytological and immunohistochemical techniques are in use in most European 
centres. Secondly, the cytopathologists were not blinded to the clinical information, they had 
information from the requesting clinician as well as from the multi-disciplinary meeting (MDT). This 
may have influenced their interpretation of the cytology specimen, but this study is a pragmatic 
assessment of the value of pleural fluid cytology in day-to-day practice. Additionally, a concern when 
using pleural fluid cytology alone to diagnose malignancy is that there is insufficient material for 
further analysis. This is increasingly relevant given the continued development of targeted 
immunotherapy for malignancies that metastasise to the pleura. In our study, given the change in 
immunohistochemistry and cytogenetic practice over the 8-year recruitment period, the suitability 
of pleural fluid specimens for further analysis is difficult to quantify. In the 41 incidences where 
receptor status or genetic analysis was requested, the pleural fluid specimen was sufficient in 95% of 
cases (39/41). Other studies with a focus on this issue have found that pleural fluid samples can 
reliably provide genetic information that correlates with the primary malignancy [31-34].  
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In conclusion, this is the largest prospective study of pleural fluid cytology in the literature. We have 
shown considerable variation in the sensitivity of cytological assessment by primary cancer type with 
adenocarcinoma, especially ovarian, having especially high sensitivity. Haematological malignancy 
and mesothelioma were unlikely to be diagnosed with pleural cytology alone. This information can 
help to inform discussions with patients around the likelihood of needing further investigations for 
pleural effusions. In asbestos exposed male patients with an exudative effusion and no history of 
cancer, a strategy of not waiting for the cytology result before organising further tests is justifiable 
and would speed up the diagnostic and treatment pathway.  
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